Nanomedicine-driven tumor glucose metabolic reprogramming for enhanced cancer immunotherapy.
10.1016/j.apsb.2025.04.002
- Author:
Chenwei JIANG
1
;
Minglu TANG
1
;
Yun SU
2
;
Junjie XIE
3
;
Qi SHANG
1
;
Mingmei GUO
1
;
Xiaoran AN
1
;
Longfei LIN
4
;
Ruibin WANG
5
;
Qian HUANG
6
;
Guangji ZHANG
7
;
Hui LI
4
;
Feihu WANG
1
Author Information
1. School of Biomedical Engineering, Shanghai Jiao Tong University, Shanghai 200240, China.
2. Department of Ophthalmology, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200011, China.
3. School of Chemistry and Chemical Engineering, Shanghai Jiao Tong University, Shanghai 200240, China.
4. Institute of Chinese Materia Medical, China Academy of Chinese Medical Sciences, Beijing 100700, China.
5. Instrumental Analysis Center, Shanghai Jiao Tong University, Shanghai 200240, China.
6. Monyan Pharmaceutical (Shanghai) Co., Ltd., Shanghai 201400, China.
7. School of Basic Medical Sciences, Zhejiang Chinese Medical University, Hangzhou 310053, China.
- Publication Type:Review
- Keywords:
Cancer immunotherapy;
Glucose metabolism;
Glycolysis;
Lactate;
Nanomedicine
- From:
Acta Pharmaceutica Sinica B
2025;15(6):2845-2866
- CountryChina
- Language:English
-
Abstract:
Tumors exhibit abnormal glucose metabolism, consuming excessive glucose and excreting lactate, which constructs a tumor microenvironment that facilitates cancer progression and disrupts immunotherapeutic efficacy. Currently, tumor glucose metabolic dysregulation to reshape the immunosuppressive microenvironment and enhance immunotherapy efficacy is emerging as an innovative therapeutic strategy. However, glucose metabolism modulators lack specificity and still face significant challenges in overcoming tumor delivery barriers, microenvironmental complexity, and metabolic heterogeneity, resulting in poor clinical benefit. Nanomedicines, with their ability to selectively target tumors or immune cells, respond to the tumor microenvironment, co-deliver multiple drugs, and facilitate combinatorial therapies, hold significant promise for enhancing immunotherapy through tumor glucose metabolic reprogramming. This review explores the complex interactions between tumor glucose metabolism-specifically metabolite transport, glycolysis processes, and lactate-and the immune microenvironment. We summarize how nanomedicine-mediated reprogramming of tumor glucose metabolism can enhance immunotherapy efficacy and outline the prospects and challenges in this field.
